3 studies found for:    ACR16
Show Display Options
Rank Status Study
1 Completed A Study of Treatment With ACR16 in Patients With Huntington's Disease
Condition: Huntington's Disease
Interventions: Drug: ACR16;   Drug: Placebo
2 Completed A Study of ACR16 for the Treatment of Patients With Huntington's Disease
Condition: Huntington Disease
Interventions: Drug: ACR16 10 mg;   Drug: ACR16 22.5 mg;   Drug: ACR16 45 mg;   Other: Placebo
3 Active, not recruiting Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Condition: Huntington Disease
Intervention: Drug: pridopidine

Indicates status has not been verified in more than two years